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SUMMARY
Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal
osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation.
Here, we present a computational approach on the basis of coupling a pharmacokinetics model of deno-
sumab with a pharmacodynamics model for quantifying the effect of denosumab on bone remodeling. The
pharmacodynamics model comprises an integrated systems biology-continuum micromechanics approach,
including a bone cell population model, considering the governing biochemical factors of bone remodeling
(including the action of denosumab), and a multiscale micromechanics-based bone mechanics model, for
implementing the mechanobiology of bone remodeling in our model. Numerical studies of postmenopausal
osteoporosis show that denosumab suppresses osteoclast differentiation, thus strongly curtailing bone resorp-
tion. Simulation results also suggest that denosumab may trigger a short-term bone volume gain, which is,
however, followed by constant or decreasing bone volume. This evolution is accompanied by a dramatic
decrease of the bone turnover rate by more than one order of magnitude. The latter proposes dominant
occurrence of secondary mineralization (which is not anymore impeded through cellular activity), leading
to higher mineral concentration per bone volume. This explains the overall higher bone mineral density
observed in denosumab-related clinical studies. Copyright © 2013 John Wiley & Sons, Ltd.
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1. INTRODUCTION
Osteoporosis is a disease characterized by significant bone loss, leading to an increased risk of bone
fracture. It is particularly common in postmenopausal women and the elderly. Often postmenopausal
osteoporosis (PMO) is first apparent from a bone density scan, and for this reason it is sometimes
called the “silent disease”, as there may be no noticeable symptoms associated with bone loss [1].
Once detected, various ways to limit further bone loss or induce bone gain have been tried clinically.
These include dietary changes and exercise, and different drug treatments that influence the turnover
of bone, including administration of bisphosphonates and parathyroid hormone (PTH) [2–4].
Recently, Amgen [5] developed a monoclonal antibody named denosumab for the treatment of
osteoporosis. Denosumab binds with high affinity and specificity to the molecule known as RANKL,
the ligand of the receptor activator of nuclear factor kappa-B [6], which is essential for the develop-
ment of active osteoclasts – osteoclasts are the cells responsible for bone resorption [7]. Following
the successful completion of more than 30 clinical trials involving a large number of patients [8–12],
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denosumab is now available for the treatment of osteoporosis and is marketed for this purpose under
the name Prolia [13], whereas denosumab is also marketed under the name Xgeva for the purpose
of treating of bone cancer metastases.
Anticipating the progression of PMO and the effects of therapeutic agents (such as denosumab)
on the basis of experimental observations alone is difficult (if not impossible), owing to com-
plex interactions between the cells governing the bone physiology in health and disease. Hence,
experiment-based drug design is a lengthy and expensive process. Given the continuously increasing
capability of computer simulations, supporting and complementing the design of drug admin-
istration regimes by computational modeling has proven promising [14–16]. The gold standard
of mathematical modeling of disease systems comprises coupling pharmacokinetic (PK) models
(quantifying the “availability” of the drug at sites of interest) with pharmacodynamic (PD) models
(quantifying the time-dependent effect of the drug on the overall physiological system). Most of pre-
vious PK/PD-type models relate, on a simplistic phenomenological basis, drug exposure to related
levels of so-called biomarkers, which serve as indicators for drug effectiveness and safety [17–19].
While state-of-the-art approaches, see for example the works of Marathe et al. [20], Pivonka et al.
[21], or Peterson and Riggs [22], provide valuable qualitative insights on the effects of drug admin-
istration, two major shortcomings are evident in any of the state-of-the-art models we found in the
literature:
(i) The studied disease is usually driven through a constant change of certain parameters. How-
ever, as pointed out by Post et al. [19], it is essential to consider the experimentally observed
time-dependence of the biological factors triggering progressive, chronic diseases such
as PMO.
(ii) Bone remodeling is driven solely biochemically, without consideration of biomechanical
feedback. It is, however, beyond any doubt [23] that bone remodeling is regulated both
biochemically and biomechanically.
In this paper, we aim at resolving these shortcomings by developing and integrating computa-
tional models in an attempt to better understand the mechanism(s) of the action of denosumab on
remodeling events in bone. We also take into consideration the clinically observed increase in bone
density following treatment with denosumab. Remarkably, this observation is a counterintuitive clin-
ical outcome as preventing bone resorption (which is the functional principle of anti-catabolic drugs
such as denosumab) does not, by itself, imply any bone gain. In particular, we aim at explaining
how the binding of RANKL by denosumab may be related to the clinically observed increase in
bone density.
For these purposes, we first develop a PK model, on the basis of the experimental data of
Bekker et al. [8], that predicts the blood serum concentration of denosumab following subcuta-
neous administration (Section 2). We then link this PK model to a recently developed integrated
systems biology-continuum micromechanics model of bone remodeling [24]. This model takes into
account key features of the known physiology of bone remodeling, including the most significant
biochemical and biomechanical regulatory mechanisms (Section 3.1). Here, the model of Scheiner
et al. [24] is extended: (i) to enable adequate simulation of the effects of PMO on bone remod-
eling (Section 3.2), and (ii) to also provide the pharmacodynamical effects of the exogenous drug
denosumab (Section 3.3). We utilize our model then for simulation of PMO without administration
of denosumab (Section 4.1), and we study the effects of single administration and multiple admin-
istrations of denosumab (Sections 4.2 and 4.3), and interpret the results through comparison with
experimental data from biomarker measurements (Section 5.1) and from bone mineral density mea-
surements (Section 5.2). After discussing the influence of the mechanical loading on the disease
progress (Section 5.3), we round the paper off with concluding remarks (Section 6).
2. PHARMACOKINETICS OF DENOSUMAB
Denosumab is injected subcutaneously and over time is absorbed into the blood serum. Through
blood circulation, denosumab may then reach surfaces of metabolizing bone. Mathematical descrip-
tion of the effect of denosumab requires formulation of a PK model taking into account the delay
between drug administration and effectivity.
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Figure 1. Pharmacokinetics model representation of denosumab: compartment I represents the subcutaneous
tissue with denosumab being present at mass concentration mden,sub, whereas compartment II represents the
blood serum with denosumb being present at mass concentration mden,ser; the compartment concentrations
are governed by absorption rate kabs, degradation rates korg and kenz, and the administered dose Dden (which
is related to mden,sub).
To this end, in line with Marathe et al. [20], a two-compartment representation [25] of the
physiological system is chosen, with compartment I relating to the subcutaneous tissue, in which
denosumab is present at mass concentration mden,sub, and compartment II relating to the blood serum,
in which denosumab is present at mass concentration mden,ser, see Figure 1. The transfer of deno-
sumab from the subcutaneous tissue to the blood serum is governed by absorption rate kabs. We
take into account that in the blood serum denosumab is subjected to degradation (also referred to as
clearance) by both organs and enzymes. Degradation by organs is considered via degradation rate
korg, whereas degradation by enzymes is considered via degradation rate kenz.
2.1. Governing equations for calculation of the denosumab concentrations
For development of a mathematical model describing the pharmacokinetics of denosumab, we
assume that the absorption of denosumab from the subcutaneous tissue into the blood serum is
linearly related to the actual mass (concentration) mden,sub in the subcutaneous tissue. Accordingly,
dmden,sub
dt
D kabsmden,sub . (1)
Solution of Equation (1) requires consideration of an appropriate initial condition. In a single-dose
administration regime, with denosumab administered at t D 0, t being the time variable, mden,sub
is the sudden increase of mden,sub in the subcutaneous tissue due to the administered dose Dden,
and prior to denosumab administration the concentration of denosumab in the subcutaneous tissue
equals zero. Based on this initial condition, Equation (1) can be solved analytically, see Equation
(A.1) in Appendix A.
In the blood serum, denosumab degradation occurs proportional to its actual concentration
mden,ser. However, experimental findings [26] suggest that above a certain limit concentration, here-
after denoted as mcritden,ser, degradation is restricted. Following classical literature on enzyme kinetics
[27], we include in our PK model that this degradation restriction can be attributed to a limited
degradation capacity of the involved enzymes. In mathematical terms, the serum concentration of
denosumab is hence governed by
dmden,ser
dt
D
(
kabsmden,sub  .korg C kenz/mden,ser if mden,ser 6 mcritden,ser
kabsmden,sub  korgmden,ser  kenzmcritden,ser if mden,ser > mcritden,ser
(2)
Prior to administration of denosumab, at t D 0, the denosumab serum concentration equals zero,
thus mden,ser.t D 0/ D 0. Due to absorption of denosumab from the subcutaneous tissue mden,ser
builds up over time, governed by Equation (2)1, and arrives at limit concentration mcritden,ser at t D t critini .
For t > t critini the evolution of mden,ser follows Equation (2)2 (because mden,ser > mcritden,ser). After reach-
ing a dose-dependent peak concentration, mden,ser decreases, because of the decreasing supply from
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the subcutaneous tissue, until it reaches again mcritden,ser at t D t critend. For t > t critend the serum con-
centration is smaller than the limit concentration and hence again governed by Equation (2)1. On
the basis of these conditions, Equation (2) can be solved for mden,ser, see Equations (A.2)–(A.4)
in Appendix A.
Depending on the administration intervals and the delivered doses, a denosumab administration
regime involving multiple administrations is characterized by a large number of possible initial
and boundary conditions on the basis of which the Equations (1) and (2) have to be solved, see
Appendix A.
2.2. Calibration of the absorption and degradation rates
Now, the PK model derived in Section 2.1 and Appendix A is calibrated through determination
of parameters kabs, korg, and kenz. For this purpose, we use the clinical data of Bekker et al. [8],
who measured the temporal evolutions of the serum concentration for six different administration
Figure 2. Calibration of the denosumab pharmacokinetics model against the clinical data of Bekker et al. [8]:
(a) comparison between temporal evolutions of model-predicted and measured serum concentrations, and
(b) model-predicted versus measured serum concentrations; DBek,4den D 0.3 mg/kg, DBek,5den D 1.0 mg/kg, and
D
Bek,6
den D 3.0 mg/kg.
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doses DBek,1den D 0.01 mg/kg, DBek,2den D 0.03 mg/kg, DBek,3den D 0.1 mg/kg, DBek,4den D 0.3 mg/kg,
D
Bek,5
den D 1.0 mg/kg, and DBek,6den D 3.0 mg/kg. A two-membered evolution algorithm [28] is
employed for determination of absorption and degradation rates, aiming at minimization of the
relative error between computed and experimentally determined serum concentrations.
Dosing of denosumab occurs relative to the patient body mass. For conversion of the administered
dose into a corresponding increase of mden,sub, we consider an average subject body weight of 70 kg
[29], and a blood serum volume of 3 liters [30], resulting in mden,sub [ng/ml] D 2.P3Dden [mg/kg] 
104. Because, for patient convenience, denosumab administration regimes preferably involve a small
number of high-dose administrations rather than a large number of low-dose administrations, we
consider only doses DBek,4den , D
Bek,5
den , and D
Bek,6
den for model calibration, to focus on practically relevant
doses. Furthermore, the experimental data of Bekker et al. [8] show that above a serum concentration
of  750 ng/ml, denosumab degradation kinetics are restricted, thus mcritden,ser D 750 ng/ml. On this
basis, the implemented evolution algorithm yields kabs D 1.8498 month1, korg D 0.9500 month1,
and kenz D 0.9932 month1, see Figure 2 for a comparison of clinical data to PK model results.
3. THEORETICAL BASIS FOR MODELING THE EFFECT OF DENOSUMAB ON
REMODELING OF BONE SUBJECTED TO POSTMENOPAUSAL OSTEOPOROSIS
3.1. A bio-chemo-mechanically coupled mathematical model of bone remodeling
The main novelty presented in this paper, namely a mathematical model enabling simulation of the
effect of denosumab on bone remodeling within a representative volume element of bone subjected
to PMO, is centered around a recently developed model integrating bone cell population kinet-
ics and multiscale bone mechanics [24]. For conciseness, we here present the model components
as follows: While model extensions that are original contributions of this paper are presented at
appropriate length, any model components borrowed from previous publications are only outlined
briefly.
3.1.1. General remarks. The previously developed and here utilized integrated approach to com-
putational simulation of bone remodeling [24] is based on the notion of a representative volume ele-
ment (RVE). Within an RVE of bone microstructure (with a characteristic length of 1 to 3 mm), bone
remodeling, together with the underlying biochemistry and the mechanical environment, occurs
(quasi-)homogeneously. Hence, spatial effects (such as transport processes and local variations of
biochemical factors or mechanical properties) can be neglected.
3.1.2. Bone cell population kinetics. The biochemically and biomechanically guided evolutions
of osteoblasts (the cells responsible for bone formation) and osteoclasts (the cells responsible for
bone resorption) are mathematically modeled by means of a so-called bone cell population model
(BCPM), the foundation of which was laid by Lemaire et al. [31], explicitly considering various dis-
tinct developmental stages of osteoblasts and osteoclasts. Namely, the model takes into account the
populations of uncommitted osteoblast progenitor cells (abbreviated to OBu), osteoblast precursor
cells (OBp), active osteoblasts (OBa), osteoclast precursor cells (OCp), and active osteoclasts (OCa).
The populations of these cell types are expressed in terms of respective molar concentrations Ci
(describing the “amount” of the species per unit volume and being thus equivalent to corresponding
average cell numbers). Progression of osteoblasts and osteoclasts along the chosen developmental
stages (OBu ! OBp ! OBa and OCp ! OCa) is implemented considering the (regulatory) mech-
anisms described in the following paragraphs, see Figure 3 and [21, 24, 32], as well as references
therein, for details on the mathematical implementation.
The concentration of the OBps, COBp , increases because of differentiation of OBus (which are
assumed to exhibit a constant concentration), governed by maximum differentiation rate DOBu and
activated through binding of transforming growth factor ˇ (TGF-ˇ) to its receptors [34,35], via acti-
vator function TGF-ˇact,OBu ; it further increases because of proliferation of OBps, governed by maximum
proliferation rate POBp and activated through increased mechanical loading [36–39], by means of
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Figure 3. Graphical sketch, adapted from Pivonka et al. [33], showing all mechanisms considered in
the model presented in this paper, with novel contributions colored green and red: guidance of cell
developments (OBu ! OBp ! OBa and OCp ! OCa) occurs biochemically (governed by TGF-ˇ
and the RANK-RANKL-OPG pathway, including the action of PTH) via related activator and repressor
functions, act and rep, and biomechanically (the macroscopic loading † relates to microscopic loading
 bm, causing microscopic deformations represented by the microscopic strain energy density ‰bm, the latter
entering the bone cell population model); evolutions of the different cell developmental stages follows cell
differentiation (considered through maximum differentiation rates DOBu , DOBp , and DOCp ), cell proliferation(considered through maximum proliferation rate POBp ), and cell apoptosis (considered through maximum
apoptosis rates AOBa and AOCa ); the mechanisms based on which the effects of PMO and denosumab
administration, respectively, are depicted in the red-colored box (dotted thick lines) and in the green-colored
box (dashed thick lines), respectively; see Sections 3.2–3.4 for details on related model extensions.
activator function …mechact,OBp , see Equation (7) and [24] for details; and it decreases because of dif-
ferentiation of OBps to OBas, governed by maximum differentiation rate DOBp and inhibited by
binding of TGF-ˇ to its receptors [34, 35], via repressor function TGF-ˇrep,OBp :
dCOBp
dt
D DOBuCOBuTGF-ˇact,OBu C POBpCOBp…mechact,OBp  DOBpCOBp
TGF-ˇ
rep,OBp . (3)
The concentration of the OBas, COBa increases because of differentiation of OBps, governed by
maximum differentiation rate DOBp and inhibited through binding of TGF-ˇ to its receptors, via
repressor function TGF-ˇrep,OBp ; and it decreases because of apoptosis governed by constant apoptosis
rate AOBa :
dCOBa
dt
D DOBpCOBpTGF-ˇrep,OBp  AOBaCOBa . (4)
The concentration of the OCas, COCa increases because of differentiation of OCps (which are
assumed to exhibit a constant concentration), governed by maximum differentiation rate DOCp
and activated through binding of receptor activator nuclear factor kappa ˇ (RANK) to its ligand,
RANKL, via activator function RANKLact,OCp ; and it decreases because of apoptosis, governed by maxi-
mum apoptosis rate AOCa and activated through binding of TGF-ˇ to its receptors [40], via activator
function TGF-ˇact,OCa :
Copyright © 2013 John Wiley & Sons, Ltd. Int. J. Numer. Meth. Biomed. Engng. 2014; 30:1–27
DOI: 10.1002/cnm
MATHEMATICAL MODELING OF OSTEOPOROSIS TREATMENT BY DENOSUMAB 7
dCOCa
dt
D DOCpCOCpRANKLact,OCp  AOCaCOCaTGF-ˇact,OCa . (5)
Note that RANKLact,OCp , further specified in Section 3.3, also considers the influence of the parathyroid
hormone (PTH) and osteoprotegerin (OPG) on binding of RANK to RANKL [6], as well as the
reduction of RANKL production because of increasing mechanical loading [41–44], see Equation
(8) and [24, 32] for details.
Activator functions TGF-ˇact,OBu , 
TGF-ˇ
act,OCa , and 
RANKL
act,OCp , as well as repressor function 
TGF-ˇ
rep,OBp are
defined according to the concept of Hill functions [45], governed by concentrations of the respective
substances, namely TGF-ˇ and the RANK-RANKL complex. The complete formulations of these
functions, as well as respective derivations, are given in full detail in [24, 32].
3.1.3. Relation of bone cell populations to bone composition. The considered RVE of cortical
bone is composed of extravascular bone matrix and vascular pore space.1 Importantly, we con-
sider the quasi-instantaneous character of primary mineralization [46–48] by having the modeled
osteoblasts deposit directly mineralized solid bone matrix, thereby omitting consideration of the
initially laid down unmineralized osteoid. For the mineralized bone matrix, we consider a con-
stant, organ-dependent mineralization state, see Appendix B and [24, 49] for further details. The
“amount” of the aforementioned components within the studied RVE, namely extravascular bone
matrix and vascular pore space, is quantified by means of volume fractions: the volume fraction of
extravascular bone matrix is defined as its volume within the RVE divided by the total volume of
the RVE, fbm D Vbm=VRVE; the volume fraction of vascular pore space, fvas, is defined analogously,
fvas D Vvas=VRVE. A numerical value of fbm D 1 thus expresses that the RVE consists solely of
extravascular bone matrix, in turn implying fvas D 0 (because fbm Cfvas  1). Dealing with cortical
bone only, the initial bone composition in all simulations presented in Section 4 is defined through
f inibm D 0.95. The change of volume fractions is governed by bone resorption and bone formation.
To relate the bone cell concentrations COCa and COBa , obtained from the BCPM, to corresponding
changes of the bone constituent volume fractions, we define resorption rate kres, quantifying how
much bone is resorbed per concentration of active osteoclasts, and formation rate kform, quantifying
how much bone is formed per concentration of active osteoblasts:
dfvas
dt
D dfbm
dt
D kresCOCa  kformCOBa . (6)
Accordingly, kresCOCa D kformCOBa represents equilibrated bone remodeling (with constant bone
constituent volume fractions fbm and fvas), kresCOCa > kformCOBa represents a catabolic bone
remodeling regime (where fvas increases), while kresCOCa < kformCOBa represents an anabolic
bone remodeling regime (where fbm increases).
3.1.4. Mechanical regulation of bone remodeling. In line with Scheiner et al. [24], we consider
the strain energy density that is experienced by the extravascular bone matrix, ‰bm, as adequate
mechanoregulatory quantity; in other words, the current magnitude of ‰bm dictates whether and to
which extent addition or removal of bone is triggered by the mechanical loading. Estimation of ‰bm
is accomplished by means of a continuum micromechanics-based [50] multiscale bone mechan-
ics model [49]: Based on the morphology of the RVE, on the intrinsic, experimentally accessible
stiffnesses of the bone constituents (extravascular bone matrix and pore space), and on the corre-
sponding volume fractions accessible through evaluation of the bone cell concentrations obtained
1Note that, in terms of evaluation of the model presented in Sections 3 and 4, we restrict ourselves to cortical bone.
Extension of the model to trabecular bone is straightforward, merely requiring adjustment of some model parameters.
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from the BCPM, see Equation (6), the microscopic strain tensor of the extravascular bone matrix,
"bm, is estimated. ‰bm follows then through ‰bm D 1=2."bm W cbm W "bm/, with cbm denoting the
microscopic stiffness tensor of the extravascular bone matrix (see Appendix B for the numerical
values of the components of cbm), and “W” denoting a mathematical operation called second-order
tensor contraction. Note that cbm relates "bm to the microscopic stress tensor  bm through a linear
constitutive relation,  bm D cbm W "bm.
Importantly, continuum micromechanics allows to “downscale” the stresses †cort, acting upon the
bone on the macroscale, to the related strain tensor "bm on the microscale. For the sake of simplic-
ity, we prescribe, in all simulations presented in Section 4, a constant, uniaxial compression loading
scenario, with †33 D 30 MPa.2 In our model, both mechanically governed activation of OBp pro-
liferation and mechanically governed production of RANKL are regulated by ‰bm [24], establishing
a feedback-type relation between bone biology and bone mechanics:
…mechact,OBp D M…mechact,OBp

1 C 

‰bm
M‰bm
 1

, (7)
P mechRANKL D 

1  ‰bmM‰bm

. (8)
In Equation (7), M…mechact,OBp denotes the value of …mechact,OBp related to “normal” mechanical loading,
which, in turn, induces a corresponding SED M‰bm, M…mechact,OBp D 0.5; note that …mechact,OBp governs the
osteoblast precursor proliferation in Equation (3). The sensitivity of OBp proliferation to increased
mechanical loading can be adjusted by the so-called anabolic strength parameter . This parame-
ter has been found to reasonably replicate mechanically stimulated bone gain if set to  D 1.25
if ‰bm > M‰bm, and  D 0 if ‰bm 6 M‰bm [24]. In Equation (8), P mechRANKL denotes the production
of RANKL because of decreased mechanical loading (compared with normal loading conditions).
In our model, P mechRANKL co-governs the concentration of RANKL, see Equation (12) and below, this
way modulating the differentiation of OCp to OCa. Inhibition parameter  allows for adjustment of
the sensitivity of RANKL production to a reduced mechanical loading. Setting  D 105 pM/day if
‰bm 6 M‰bm and  D 0 if ‰bm > M‰bm has proven to give rise to reasonably simulated bone loss if
subjected to disuse scenarios [24].
3.2. Consideration of the effect of postmenopausal osteoporosis on bone remodeling
Experimental studies on the pathophysiology of PMO reveal that several mechanisms might occur
simultaneously, together inducing the disease pattern known as PMO. Among several other poten-
tial pathogenic mechanisms, estrogen deficiency3 has been widely accepted as the main cause
of PMO [51, 52], resulting in increased osteoclast and osteoblast concentrations (and thus in an
increased bone turnover) [53]. Relative to the cell concentrations in healthy (premenopausal) bone,
the increase of COCa is higher than the increase of COBa that leads to (potentially) significant
bone loss after onset of PMO. This initial phase of PMO is accompanied by an increased ratio
of the RANKL concentration over the OPG concentration, compared with normal bone physiol-
ogy [54]. After some time (some months up to a few years), the rate of bone loss decreases, and
postmenopausal bone is subjected to long-lasting moderate bone loss thereafter.
Driving PMO biochemically can be achieved in different ways; see [21] for a related study. Estro-
gen and its role in bone remodeling is not considered explicitly in our model, so PMO cannot be
2However, the micromechanical model employed here is able to straightforwardly consider any desired load case; see
reference [24] and Section 5.3 for a discussion on the influence of the mechanical loading on the model predictions.
3Estrogen inhibits osteoclastogenesis; that is, maturation of osteoclastic cells [54, 55]. Menopause entails a significant
drop of the estrogen level, consequently leading to omission of this inhibition, followed by increased osteoclast activity
and thus loss of bone.
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simulated by feeding experimentally observed estrogen levels into the model. Instead, PMO is initi-
ated by introducing disease-related increased production of RANKL, leading to increased osteoclast
differentiation. In order to account for the moderate bone loss in the second phase of PMO, it is
assumed that the excess production of RANKL reduces over time. In detail, we prescribe the fol-
lowing RANKL production regime for t > tPMO,ini, with tPMO,ini being the point in time when PMO
is initiated:
P PMORANKL D P PMO,iniRANKL 'RANKLPMO , (9)
with P PMO,iniRANKL as PMO-initiating excess production rate of RANKL, and with 'RANKLPMO as a reduction
factor of P PMO,iniRANKL , which we define as
'RANKLPMO D
2
2 C

t  tPMO,ini
RANKLPMO
2 . (10)
Parameter  and the characteristic time of the RANKL production decrease, RANKLPMO , together
determine the shape of the Lorentz-type function given by Equation (10). In our model, P PMORANKL
co-governs the concentration of RANKL, see Equation (12) and below, this way modulating the
differentiation of OCps to OCas. Furthermore, in vivo data suggests that the decreasing mechanore-
sponsiveness of bone due to increased osteocyte apoptosis, another effect of estrogen deficiency,
also plays a major role for the progression of PMO [52, 56]. In order to incorporate this effect into
our model we assume that, after onset of PMO at t D tPMO,ini, the parameters governing the sensi-
tivity of bone remodeling to a changing mechanical loading,  and , see Equations (7) and (8), are
decreased via reduction factor 'mechPMO ,
'mechPMO D exp

t  tPMO,ini
mechPMO

, (11)
with PMO as the characteristic time of the PMO-related mechanoresponsiveness decrease of corti-
cal bone. Hence, contrary to conventional PK/PD approaches, in our model the disease-governing
parameters are not held constant, but are varied over time, following the pathophysiological trends
reported in the literature [19].
The set of Equations (9)–(11) can be considered as a (semi-)phenomenological approach to the
sum of processes that in reality contribute to initiation and maintenance of PMO. While such an
approach is common practice for simulation of complex physiological systems, the model parame-
ters introduced in this section cannot be measured or directly deduced from experimental data. Thus,
for the time being, we are content with adjusting these parameters such that simulation results agree
well with corresponding experimental data, as demonstrated in Section 4.1.
3.3. Incorporation of the action of denosumab
In our model, denosumab contributes to regulation of osteoclast differentiation via activator func-
tion RANKLact,OCp . Denosumab competes with RANK (and OPG) as for binding to RANKL, meaning the
higher the concentration of denosumab the lower the concentration of RANKL-RANK complexes,
hence the lower the numerical value of RANKLact,OCp and the lower the fraction of the osteoclast precursor
population that differentiates into active osteoclasts. Adapting the approach of Pivonka et al. [32],
the concentration of RANKL follows
CRANKL DC maxRANKL
ˇRANKL C PRANKL
ˇRANKL C QDRANKLC maxRANKL
Œ1 C Ka,[RANKL-OPG]COPGC
CKa,[RANKL-RANK]CRANK C Ka,[RANKL-d]Cden,ser	1 ,
(12)
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where Ka,[RANKL-OPG], Ka,[RANKL-RANK], and Ka,[RANKL-d] are the equilibrium association binding
constants for binding of OPG, RANK, and denosumab to RANKL, COPG, CRANK, and Cden,ser are
the molar concentrations of OPG, RANK, and denosumab, ˇRANKL is the intrinsic RANKL produc-
tion rate, PRANKL is the RANKL dosage term, QDRANKL is the constant degradation rate, and C maxRANKL
is the maximum concentration of RANKL. The concentration of RANKL-RANK complexes is
considered through
CŒRANKL-RANK D Ka,[RANKL-RANK]CRANKLCRANK . (13)
While the BCPM and respective concentrations of regulatory factors are formulated for a spe-
cific RVE of bone tissue, the concentration of denosumab is given in the blood serum. In Equation
(12), the varying accessibility of denosumab to different RVEs of bone tissue is taken into account
through accessibility factor :  D 1 represents unrestricted access to denosumab, whereas  < 1
reflects access restrictions (for example because of low or uneven blood circulation). In the follow-
ing, we only consider the case of uniform and sufficient blood circulation,  D 1. Finally, activator
function RANKLact,OCp is governed by [32]
RANKLact,OCp D
CŒRANKL-RANK
Kd,[RANKL-d] C CŒRANKL-RANK , (14)
with Kd,[RANKL-d] as the corresponding equilibrium dissociation binding constant. In the present
model, the external production rate of RANKL, PRANKL, is made up of two components: P mechRANKL
(stemming from decreased mechanical loading), see Equation (8), and P PMORANKL (for simulation of
postmenopausal osteoporosis, see Equation (9), PRANKL D P mechRANKL C P PMORANKL.
3.4. Governing model parameters
The interaction of RANKL and denosumab is considered via the denosumab serum concentra-
tion mden,ser, see Section 2, and the association binding constant Ka,[RANKL-d] which quantifies the
affinity of denosumab-binding to human RANKL. Choice of the numerical value of Ka,[RANKL-d]
is based on the in vitro experiments performed by Kostenuik et al. [57]. Solution equilibrium
binding analysis revealed an equilibrium dissociation binding constant of Kd,[RANKL-d]  3 pM.
The equilibrium association binding constant is defined as the inverse of the corresponding dis-
sociation constant, Ka,[RANKL-d] D .Kd,[RANKL-d]/1  0.33 pM1. Furthermore, the denosumab
concentrations provided by the PK model are given in ng/mg, whereas the unit of the equilibrium
association binding constant is pM1 D .1012 mol/l/1. Hence, PK model-derived mass con-
centrations mden,ser have to be converted to the corresponding molar concentration Cden,ser. This
conversion follows from fundamental principles of physical chemistry [58]: Given the molecular
weight of denosumab, Mden D 147 kDa [59], the molar concentration corresponding to a mass
concentration of mden,ser D 1 ng/ml is Cden,ser D 6.8027 pM.
Further model calibration has been thoroughly dealt with in [21, 24, 32]; the numerical values of
the parameters that are explicitly mentioned in this paper are summarized in Appendix B.
4. NUMERICAL STUDIES
4.1. Simulation of postmenopausal osteoporosis without administration of denosumab
In this section, the model introduced in Section 3.2 is calibrated such that porosity evolutions
observed clinically during PMO progression [60] can be replicated, yielding P PMO,iniRANKL D 0.6 
104 pM/d,  D 65, RANKLPMO D 10 d, and mechPMO D 900 d, compare Equations (9) and (10). Considering
the such defined PMO-related RANKL-production and the decline of the mechanoresponsiveness
of cortical bone, see Figure 4(a), yields corresponding evolutions of osteoclast and osteoblast con-
centrations, see Figure 4(b). The corresponding increase of the vascular porosity over time agrees
well with physiologically observed porosity evolutions in osteoporotic bone [60], see Figure 4(c).
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(a) (b)
(c) (d)
Figure 4. Simulation of postmenopausal osteoporosis (PMO) with disease initiation at tPMO,ini D 0:
(a) prescribed temporal evolutions of the reduction factor of the disease-related RANKL production rate,
'RANKLPMO , and of the mechanoresponsiveness reduction factor, 'mechPMO , (b) model-predicted evolutions of
the concentrations of active osteoclasts, COCa , and active osteoblasts, COBa , normalized with respect to the
concentration before onset of PMO, C preOCa D COCa.t < tPMO,ini/ and C
pre
OBa D COBa.t < tPMO,ini/, (c) the
increase of the vascular porosity of osteoporotic cortical bone over time, fvas.t/, simulated by our model,
compared with corresponding experimental results, and (d) the phase diagram comparing bone resorption
versus bone formation responses associated to the simulated porosity increase of osteoporotic cortical bone;
the arrows indicate path directions.
Alternatively, to elucidate the bone remodeling kinetics leading to such porosity evolution,
the simulation results can be plotted in terms of a comparison of resorbed bone per time (bone
resorption rate times concentration of active osteoclasts, kresCOCa) versus formed bone per time
(bone formation rate times concentration of active osteoblasts, kformCOBa), see Figure 4(d) – such
graphical presentation is also referred to as “phase diagram”. A balanced bone turnover implies
kresCOCa D kformCOBa , and related data points lie on the diagonal line in Figure 4(d). A catabolic
bone remodeling regime, indicated as light grey-shaded area in Figure 4(c), is characterized by
dominating bone resorption, thus kresCOCa > kformCOBa , and corresponding data points lie below
the diagonal line.
On the other hand, an anabolic regime, indicated as light dark-shaded area in Figure 4(d), is char-
acterized by dominating bone formation, thus kresCOCa < kformCOBa , and corresponding data points
lie above the diagonal line.
Onset of PMO, at t iniPMO D 0, leads to drastically increasing bone resorption, because of a sig-
nificant, quasi-instantaneous increase of osteoclast differentiation, and thus implying an increased
osteoclast concentration, see Figure 4(b). The maximum ratio of COCa over COBa (and thus the
maximum rate of bone loss) is reached after 5.05 days, indicated by the diamond-shaped markers
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in Figure 4. Subsequently, osteoclast differentiation decreases because of decreased disease-related
RANKL-production, see Figure 4(a), thus the path of the phase diagram moves towards the diagonal
line, see Figure 4(d). Furthermore, TGF-ˇ is released during bone resorption, which leads to up-
regulation of osteoblast differentiation, indicated by the delayed increase of the osteoblast concen-
tration after onset of PMO in Figure 4(b). Osteoblasts produce RANKL, thus an increased osteoblast
concentration implies also increased RANKL production, which, in turn, leads to increased osteo-
clast differentiation and in further consequence to deceleration of the decrease of the osteoclast
concentration because of decreasing PMO-related production of RANKL, see the circle-shaped
markers in Figure 4(b). This deceleration provides the explanation for the kink observed in the phase
diagram at 76 days, see Figure 4(d). This kink is followed by decreasing bone turnover, meaning
that both bone resorption and bone formation slowly diminish. Thus, while still in the catabolic
domain, bone remodeling converges to balanced bone resorption and formation, also indicated by
the continuously flattening slope of the solid graph in Figure 4(c).
It should be noted that micromechanics-based stiffness homogenization does not only serve as an
integral part for implementing mechanoregulation of bone remodeling in our model (as described in
Section 3) but also allows for mathematical modeling-based tracking of the bone stiffness over time
(not plotted in this paper), in terms of orthotropic Young’s moduli E1, E2, and E3, shear moduli
G12, G13, and G23, and Poisson’s ratios 
12, 
13, and 
23 as stiffness-defining material properties,
see [24, 61] for details. For example, after 10 years of progressing PMO, the vascular porosity is
increased by 17.04%, see Figure 4(c), whereas Young’s moduli are decreased by up to 33.55%,
shear moduli are decreased by up to 34.64%, and Poisson’s ratios are decreased by up to 16.43%.
Hence, the effect of PMO on the mechanical integrity of bone can be significantly more severe than
the underlying change of the bone composition – in order to simulate this effect, a sound multiscale
model of bone mechanics, such as the one utilized in this paper, is essential.
4.2. Single-dose administration of denosumab
Now, we consider a regime of denosumab administration involving only one single administration,
to thoroughly elucidate general characteristics of the model response. We prescribe that denosumab
is injected 6 months4 after initiation of PMO (at t iniPMO D 0), and we investigate three different
administration doses, DIden D 0.3 mg/kg, DIIden D 1.0 mg/kg, and DIIIden D 3.0 mg/kg. Based on
these input data, the model is evaluated in terms of bone cell concentrations, as well as in terms of
corresponding phase diagrams and evolutions of the bone constituent volume fractions.
For t < 6 months (prior to administration of denosumab), all graphs (representing doses DIden,
DIIden, and DIIIden, as well as the zero dose) obviously coincide, see the paths between the square-
shaped and the circle-shaped markers in Figures 5(a)–(d). For t > 6 months, the presence of
denosumab entails inhibition of the differentiation of osteoclast precursor cells to active osteoclasts,
consequently leading to fast decrease of kresCOCa , see the paths in Figures 5(b)–(d) after passing the
circle-shaped markers. At the same time, a temporary increase of kformCOBa is observed, leading to a
short but steep increase of fbm following denosumab administration, see Figure 5(e). This increase,
indicated by the phase diagram paths crossing the balanced turnover-representing diagonal lines in
Figures 5(b)–(d), stems from how the action of TGF-ˇ is considered in our model. On the one hand,
TGF-ˇ inhibits differentiation of osteoblast precursor cells to active osteoblasts. Administration of
denosumab leads to downregulation of the concentration of active osteoclasts, entailing a reduced
release of TGF-ˇ, and in further consequence an increase, due to reduced differentiation inhibition,
of the concentration of active osteoblasts. Moreover, the presence of TGF-ˇ is required for main-
taining differentiation of osteoblast progenitor cells to osteoblast precursor cells. This means that
reduction of the concentration of TGF-ˇ leads to downregulation of the aforementioned differenti-
ation process, and thus, with a certain time delay, to downregulation of the concentration of active
osteoblasts, completing the “anabolic loops” observed in Figures 5(b)–(d).
4The delay between onset of PMO and the administration of denosumab takes into account that the onset of PMO is not
noticeable in real life, thus its treatment would be initiated after PMO has already been active for some time. Increasing
or decreasing this delay implies quantitatively different simulation results; qualitative features of respective simulation
results conform, however, with the ones described here.
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(a) (b) (e)
(c) (d)
Figure 5. Simulation results obtained for administration regimes involving one administration of
denosumab: (a)–(d) phase diagrams (in logarithmic scales) for the simulated doses, (a) Dden D 0, (b)
Dden D DIden D 0.3 mg/kg, (c) Dden D DIIden D 1.0 mg/kg, and (d) Dden D DIIIden D 3.0 mg/kg, with the
temporal progress indicated by respective markers (...0 days, Þ...5 days, ...182.5 days, 5...185 days,
4...190 days, C ...250 days, B ...700 days, and F...2000 days after onset of postmenopausal osteoporosis),
and (e) the corresponding temporal evolutions of the volume fractions of the extravascular bone matrix, fbm,
as postmenopausal osteoporosis progresses.
Subsequent to the temporary dominance of kformCOBa over kresCOCa , the action of denosumab
comes to full effect, and the bone turnover is decreased to a very low level (as compared to the
initial state), kresCOCa  .kresCOCa/ini and kformCOCa  .kformCOCa/ini, see the region around
the leftwards-pointing triangles in Figures 5(b)–(d). Notably, the higher the dose of denosumab
the lower the minimum bone turnover, and the longer the duration of low bone turnover, com-
pare with the time characteristics of the phase diagrams depicted in Figures 5(b)–(d), and the
corresponding evolutions of fbm, see Figure 5(e). After clearance of denosumab, the paths of the
dose-dependent bone turnover converge to the grey-colored path in Figure 5(a), representing PMO
without administration of denosumab. In terms of the simulated evolutions of fbm, this means that
after the temporary bone gain “peak”, related to denosumab administration, subsequent evolutions
of fbm exhibit the same slope as the evolution of fbm related to PMO only (with Dden D 0), see
Figure 5(e).
The temporal evolutions of fbm, depicted in Figure 5(e), reveal a prominent characteristic of the
model. While the long-term evolution of the volume fraction of extravascular bone matrix is ade-
quate – denosumab leads, as long as the internal degradation mechanisms described in Section 2
have not led to clearance of denosumab, to a delay of further porosity increase – the short-term
response to drug administration does not quite resemble the experimentally and clinically observed
trends. The previously described temporary dominance of osteoblast activity over osteoclast activ-
ity leads, according to the model, to a short period of very fast bone gain (fbm D 0.0125 within
t  20 days), see Figure 5(e). After this short period of significant bone gain, max .dfbm=dt / D
8.12102 % day1, the model predicts constant volume fractions, relating to the decrease of bone
turnover to a very low level as shown in Figure 5(a), after which the effect of denosumab wears
off, and the volume fraction of bone matrix decreases further (consequently the volume fraction of
porosity increases), because of uninhibited progress of PMO. While increasing the dose of deno-
sumab leads to lengthening of the volume fraction “plateau”, no dosing effect on the overall bone
gain can be observed.
4.3. Multidose administration of denosumab
In order to assess the predictive capabilities of our model, Section 4.3 is devoted to simulation of
denosumab administration regimes involving multiple administrations, as commonly investigated in
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(a) (b)
(c) (d)
Figure 6. Simulation results obtained for administration regimes involving multiple administrations of
denosumab: temporal evolutions of volume fractions of the extravascular bone matrix, fbm, during pro-
gression of PMO (a) for different administered doses (DIden D 0.3 mg/kg, DIIden D 1.0 mg/kg, and
DIIIden D 3.0 mg/kg) and (c) different administration intervals (t Iden D 1 month, t IIden D 6 months,
t IIIden D 9 months, and t IVden D 12 months), as well as the corresponding phase diagrams (b) and (d),
where each loop corresponds to one of the “hills” in (a) and (c), representing one administration interval; the
paths depicted in (b) and (d) are directed counterclockwise.
experimental (in vivo) studies and in clinical practice. We present the results of simulations consider-
ing three different administered doses, DIden D 0.3 mg/kg, DIIden D 1.0 mg/kg, DIIIden D 3.0 mg/kg, and
four different intervals between administrations, t Iden D 1 month, t IIden D 6 months, t IIIden D 9 months,
t IVden D 12 months.
The simulation results are presented in terms of bone matrix volume fraction evolutions, see
Figures 6(a) and (c), and corresponding phase diagrams, see Figures 6(b) and (d), to also shed
light on the underlying bone turnover kinetics. Obviously, decreasing the administered dose leads to
decreasing the anti-catabolic effect of denosumab because of shortened suppression of PMO-driven
bone loss, see Figure 6(a). Intuitively, the same should be true for increasing the administration
interval – this is for example observed when increasing the administration interval from 9 to
12 months. However, Figure 6(c) also shows that increasing the administration interval from 1
to 6 months results, for the administered dose of Dden D 1.0 mg/kg, in a slight increase in bone
gain. On the one hand, this effect is caused by the considered mechanoregulatory mechanisms (see
Section 3.1), or in other words by the attempt of bone to re-establish its original composition (for the
investigated cortical bone related to fbm D 0.95). On the other hand, administration regimes includ-
ing multiple administrations of denosumab also exhibit the short period of fast bone gain discussed
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in Section 4.2, which can, if administered doses and administration intervals are specifically coordi-
nated, as well create an anabolic bone remodeling response – the paths of the phase diagram related
to such administration regimes remain, on average, in the anabolic domain for a longer stretch
of time.
For intervals t IIIden D 9 months and t IVden D 12 months, the long-term influence is negligible
due to the opposite effect (a short period of very fast bone loss) observed after clearance of deno-
sumab. For interval t Iden D 1 month, the concentration of denosumab constantly remains at a
sufficiently high level to maintain suppression of bone remodeling activities so the bone volume
fraction remains constant. Increasing the interval of denosumab administration from 1 to 6 months,
with the administered dose fixed at Dden D 1.0 mg/kg, results in a higher bone matrix volume
fraction: fbm.t D 10 years, t Iden D 1 month/ D 0.9262, whereas fbm.t D 10 years, t IIden D
6 months/ D 0.9304. This trend is mainly caused by bone cell kinetics, a certain combination
of bone remodeling parameters (characterizing for instance a specific patient), and denosumab
administration parameters entail. Hence, our model allows to optimize administration intervals and
doses to maximize bone gain after initiation of the administration regime. Clearly, careful tuning of
administration interval and dose is the key to obtain such optimized administration regime, which
underpins the potential benefit of supporting the design of drug administration regimes by means of
computational modeling.
While we have performed a large number of simulations (not shown here) considering different
combinations of administration doses and administration intervals, we have never observed any sig-
nificant bone volume gain. We will further discuss the relevance of this observation with respect to
experimental and clinical studies in Section 5.2.
5. DISCUSSION
5.1. Simulation results versus biomarker measurements
In physiological conditions, the direct effect of drug administration on bone remodeling at a par-
ticular bone site is hardly measurable. To nevertheless monitor the success of anti-catabolic drugs
in the treatment of PMO, so-called bone turnover markers, also referred to as biomarkers, are com-
monly used in clinical practice [53,62], measured in the urine or in the serum. The evolution of bone
resorption is tracked on the basis of bone resorption markers, such as collagen type I cross-linked
N-telopeptide (NTx), or collagen type I cross-linked C-telopeptide (CTx). Analogously, bone for-
mation can be monitored by means of bone formation markers, such as osteocalcin (OC or BGLAP),
bone-specific alkaline phosphatase (BALP or BSAP), or procollagen type I N-terminal propeptide
(PINP). While bone turnover markers provide valuable information on the overall effect of drug
administration on bone remodeling, inferring that bone remodeling is altered to the quantitatively
same extent on specific sites seems inaccurate (the reason for this is discussed in the next para-
graph). We will hence compare the model predictions with biomarker measurements in qualitative
fashion only.
Lewiecki [26] summarizes the biochemical effect of denosumab for different single-dose admin-
istrations. Compared with the results observed for placebo administration, the “reduction of NTx
levels was observed to be dose-dependent, rapid, profound (up to 84%), sustained (for up to six
months), and reversible with discontinuation”. The model-predicted evolutions of the concentration
of active osteoclasts, serving as basis for computing the results depicted in Figure 5, fit reasonably
well to these experimental observations. The only substantial difference is that after administra-
tion of denosumab the model-predicted concentration of active osteoclasts is reduced by more
than 99% (in contrast to the reported reduction of NTx levels by up to 84% [26]). This differ-
ence can be explained by considering the involved observation scales. The computational results
are based on an RVE in which the denosumab serum concentration is assumed to be uniform, thus
denosumab is fully active throughout the RVE. In contrast, blood circulation and thus the distri-
bution of denosumab is not uniform throughout the body, and clearly regions of low supply with
denosumab do not contribute to the reduction of NTx as regions where the supply is higher. Tak-
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ing this into consideration, the agreement between model predictions and experimental results is
deemed satisfactory.5
A qualitatively and quantitatively similar trend is observed for bone formation markers during
a multiple denosumab administration regime. For example Eastell et al. [63] observed a reduction
of the PINP level of up to 90% and a reduction of the BALP level of up to 50%. Considering
the importance of the actual observation scale of the results, as proposed in the previous para-
graph, the model-predicted osteoblast concentration is assumed to be (qualitatively) consistent with
experimental observations.
5.2. Simulation results versus bone mineral density measurements
Clearly, the most tangible effect of PMO is the related decrease of mechanical properties (such as
stiffness and strength), leading to an increasing susceptibility to bone fractures. In clinical practice,
the fracture risk is usually assessed by measuring the bone mineral density (BMD) by means of dual-
energy X-ray absorptiometry on sites suspected or known to be subjected to PMO and comparing
this value with the corresponding BMD in healthy bone, for example, via the so-called T-score [64].
Often, the success of anti-resorptive drugs, such as denosumab, in the treatment of osteoporosis is
assessed by measuring the BMD evolution after drug administration. These measurements are then
interpreted as follows: the higher the increase of the BMD the more potent the investigated drug.
For example, after administration of denosumab the BMD has been reported to increase by up to
2% in cortical bone and up to 9% in trabecular bone (over a time span of typically 1 to 2 years), see
for example [9, 11, 65–68]. Mineral concentrations are not included into the present version of our
mathematical model, so that a direct comparison of BMD increase with simulation results is out of
reach for the moment. However, it is very instructive to compare the increase in BMD measured on
denosumab-treated patients with the decreasing or constant bone volume predicted by our model in
Figures 5 and 6.
By definition, denosumab (and in general anti-resorptive drugs) are intended to decrease the activ-
ity of osteoclasts. Our simulation results (see Section 4), as well as measurements of bone resorption
markers [26] confirm that denosumab indeed fulfills this intention. Simultaneously, because of com-
munication between osteoclasts and osteoblasts, denosumab also entails significant decrease of the
activity of osteoblasts – confirmation of this computationally observed behavior follows from mea-
surements of bone formation markers [63]. Evidence is thus overwhelming that the increase of
bone mineral density after administration of denosumab simply cannot arise from bone gain in
the sense that osteoblasts lay down “new” osteoid. The only mechanism remaining that is able
to cause the clinically observed BMD increase after administration of denosumab is increased
bone tissue mineralization, triggered through denosumab. The following mechanism seems very
probable. Denosumab suppresses the action of RANKL, which is itself promoting the dissolution
actions by osteoclasts and osteocytes. In particular, the latter are responsible for keeping the tis-
sue mineralization degree at some limit value [69, 70], that is, inhibiting purely chemically driven
“anorganification” of bone tissue. Suppressed osteocytic dissolution action, however, would allow
for progression of the so-called secondary mineralization process, and also increase the overall
BMD, as evidenced in clinical studies [71–78]. Hence, our model gives valuable insight into the
biological and chemical processes leading to denosumab-triggered BMD increase. For the sake of
completeness, we remark that secondary mineralization-induced increase of bone tissue stiffness
with respect to Equation (A.9) is not explicitly accounted for in the present approach, adding that,
from a mechanical point of view, a rigorous multiscale approach translating mineralization degree
to tissue stiffness is at hand [70, 79].
5In our model, the “uneven” distribution of denosumab across the human body could be taken into account by prescribing
a corresponding distribution of the accessibility factor  , as introduced in Equation (12). At present, such accessibility
distribution is, however, not available from experimental data.
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5.3. Influence of the mechanical loading on the disease progress
In the computational studies presented in this paper, we have considered a constant (that is time-
invariant) uniaxial mechanical loading. It is perfectly clear that (i) such mechanical load case is a
strong simplification of the “real” loading acting onto human bone (which is presumably always
of three-dimensional nature, including nonzero shear components of the stress and strain tensors);
and that (ii) mechanical loading varies (partly significantly) between different locations distributed
across a human skeleton. In the context of the scope of this paper, the influence of a different load
case is negligible as long as it is still time-invariant, and the resulting strain energy density is of com-
parable magnitude. This is because in our model, mechanical regulation is stimulated by changes of
the strain energy density, irrespective of the exact shape of the related strain tensor. A temporarily
changing mechanical loading, on the other hand, could potentially have a great influence on the
disease progress (in terms of the resulting bone matrix volume fraction evolution); imposing such
mechanical loading “histories” is, however, beyond the scope of this paper, which is restricted to
mathematical modeling of PMO and its pharmaceutical intervention by means of the anti-resorptive
drug denosumab. For a parametric study on the influence of the type of mechanical loading on the
related bone remodeling behavior, see reference [24].
Another important model aspect, related to the mechanical loading, is the sensitivity of the bone
remodeling response to a changing (local) mechanical loading. In the simulations presented in this
paper, the macroscopic mechanical loading is held constant at all times (as discussed in the previous
paragraph). However, the disease-related increase of the vascular porosity (after the onset of PMO,
see Figures 5 and 6) implies an increase of the strains experienced by the extravascular bone matrix,
and thus an increase of the related strain energy density, which is the quantity that has been cho-
sen as mechanoregulatory stimulus. An increase of the strain energy density, beyond the value that
occurs if the studied piece of cortical bone is healthy, leads to an increase of OBp proliferation, with
the anabolic strength parameter  as governing property, compare Equations (3) and (7). In the fol-
lowing, because of the apparent importance of parameter , we elucidate the sensitivity of the model
predictions to variations of . In particular, we perform the simulations based on which Figure 6(a)
has been created (that is a denosumab administration regime involving multiple administrations,
with an administration interval of 9 months) for two alternative values of : low D 0.125 (rep-
resenting bone with low mechanoresponsiveness) and high D 12.5 (representing bone with high
mechanoresponsiveness). In Figure 7, the volume fraction of the extravascular bone matrix after
10 years of PMO progress is plotted, confirming the striking sensitivity of the model predictions to
parameter .
Figure 7. Study of the sensitivity of the model-predicted bone matrix volume fraction fbm after 10 years of
postmenopausal osteoporosis progress with respect to a varying anabolic strength parameter , computed for
an administration regime involving multiple administrations of denosumab, with a constant administration
interval tden D 9 months and administered doses Dden D 0, DIden D 0.3 mg/kg, DIIden D 1.0 mg/kg, and
DIIIden D 3.0 mg/kg.
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This parametric study also shows that the sensitivity of the model prediction to  is indirectly
proportional to the administered dose of denosumab: the higher the administered dose, the lower
the sensitivity of the bone remodeling response to variations of . Thus, careful choice of the
model parameters accounting for the mechanoresponsiveness of bone remodeling is crucial for the
mathematical model presented here in order to replicate adequate predictions.
6. CONCLUSIONS
In this paper, an integrated model has been presented, allowing for simulation of the effects of post-
menopausal osteoporosis on bone remodeling. For this purpose, a PK model of denosumab has been
developed and coupled to a bone cell population model of bone remodeling, which itself communi-
cates with a continuum micromechanics-based homogenization scheme of bone stiffness, in order
to soundly take into account mechanobiological regulatory mechanisms of bone remodeling and
corresponding changes of the bone stiffness.
The numerical studies presented in Sections 4 and 5 have shown that the new model proposed
here allows for (qualitatively and quantitatively) reasonable simulation of osteoporotic scenarios,
and of the pharmaceutical intervention through administering the anti-catabolic drug denosumab. In
particular, the simulation results have given rise to the following specific conclusions:
(i) In order to simulate PMO, the underlying mathematical model should be fed by tempo-
rally varying disease-triggering factors – in our model, PMO is driven, on the one hand,
by disease-related RANKL production, see Equations (9) and (10), and, on the other hand,
by disease-related reduction of the mechanoresponsiveness, see Equation (11). This way, not
only the postmenopausal evolution of bone volume agrees well with corresponding clinical
data, see Figure 4(c), but also the related bone turnover satisfyingly resembles the clinically
and experimentally observed dynamics – a very high bone turnover in the initial phase of
PMO is followed by a slow, long-lasting decrease converging to the normal, premenopausal
bone turnover, see Figure 4(d).
(ii) Administration of denosumab entails, because of inhibition of osteoclast differentiation, down-
regulation of both bone resorption and, with some time delay, bone formation to an ineffective
level. One administration of denosumab has the following effects on the bone turnover:
Initially, a short but significant phase of bone gain is observed, related to the time lag
between drug-related inhibition of bone resorption and bone formation. Once bone formation
is sufficiently down-regulated (approximately 5 to 10 days after denosumab administration,
depending on the administered dose), the bone turnover reduces to a negligible level. Due to
denosumab clearance, the bone turnover finally approaches the disease-related evolution, thus
altogether denosumab administration causes a delayed progress of PMO. As expected, simula-
tion results confirm that increasing the administered dose and/or decreasing the administration
interval improves the anti-catabolic effect of denosumab, compare Figures 5(b)–(e).
(iii) The model predictions obtained through simulating denosumab administration regimes involv-
ing multiple administrations, see Section 4.3, agree, in qualitative terms, well with correspond-
ing biomarker measurements.
(iv) One central component of the integrated model is the continuous estimation of the macroscopic
bone stiffness by means of a continuum micromechanics-based homogenization scheme,
appropriately taking into account the anisotropic mechanical behavior of bone. The such
computed evolution of bone stiffness could serve as basis for assessing the risk of bone failure.
These findings highlight that the model proposed here could be a promising tool for computer
simulation-based assessment of the effects of denosumab administration on osteoporotic bone. How-
ever, the results presented and discussed in Sections 4 and 5 also motivate to invest in explicit
modeling of the secondary mineralization process and its linkage to RANKL and osteocytic action.
In addition to their important role for the mineralization process (as discussed previously), osteo-
cytes are known to act as key players for sensing changes of the mechanical loading and for
transducing these changes into corresponding biochemical events, leading to increase or decrease
of the bone matrix volume fraction [23, 80–82]. In the systems biology approach employed in this
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paper, osteocytes are not considered explicitly, which clearly constitutes a limitation of the model.
Introduction of the population of osteocytes into our model, as demonstrated in alternative modeling
approaches, see for example references [83–86], is thus deemed as promising model extension, in
particular to bring the considered mechanoregulatory mechanisms closer to experimental evidence
[81, 82, 87, 88]. Furthermore, in future model extensions, we will aim at reduction of the number
of model components to the necessary minimum; this will go along with reduction of the currently
considerable number of model parameters, being another limitation of the model. These issues are
topics of ongoing research.
APPENDIX A: ANALYTICAL SOLUTIONS OF THE PHARMACOKINETICS MODEL
A.1. Single-dose administration regimes
The analytical solution of differential equation (1), under consideration of initial condition
mden,sub.t D 0/ D mden,sub, see Section 2.1, reads
mden,sub D mden,subekabst . (A.1)
Note that mden,sub is related to the administered dose Dden through consideration of an average
patient body mass and serum volume, as discussed in Section 2.2. On the other hand, the solution
of differential equations (2) is based on conditions mden,ser.t D 0/ D 0, mden,ser.t D t critini / D mcritden,ser,
and mden,ser.t D t critend/ D mcritden,ser. Solving Equations (2) for mden,ser yields
mden,ser.t 6 t critini / D
mden,subkabs
korg C kenz  kabs
h
ekabst  e.korgCkenz/t
i
, (A.2)
mden,ser.t
crit
ini 6 t 6 t critend/ D mcritden,serekorg.tt
crit
ini / C mden,subkabs
korg C kenz  kabs 


korg C kenz  kabs
korg  kabs e
kabst C kenz
korg
h
ekorgtkenztcritini C e.korgCkenz/tcritini 
ekabstcritini
i
C k
2
org  korgkabs C kenzkabs
korg.korg  kabs/ e
korgtC.korgkabs/tcritini
)
,
(A.3)
and
mden,ser.t > t critend/ D mcritden,sere.korgCkenz/.tt
crit
end/C
C mden,subkabs
korg C kenz  kabs
h
ekabst  e.korgCkenzkabs/tcritend.korgCkenz/t
i
.
(A.4)
Numerical evaluation of Equations (A.3) and (A.4) requires knowledge of time instants t critini and
t critend. If the numerical value of mcritden,ser is known, t critini and t critend are accessible implicitly via Equations
(A.2) and (A.3): Equation (A.2), evaluated for mden,ser.t D t critini / D mcritden,ser, allows for determination
of t critini , whereas Equation (A.3), evaluated for mden,ser.t D t critend/ D mcritden,ser, allows for determination
of t critend.
A.2. Multidose administration regimes
We now want to derive analytical expressions describing the denosumab serum concentration over
time for denosumab administration regimes involving multiple injections.
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Figure A.1. Two scenarios investigated for denosumab administration regimes involving multiple
injections: in scenario (i), mden,ser starts from a level below mcritden,ser in each administration interval & , while
in scenario (ii), mden,ser remains higher than mcritden,ser at all times; within one administration interval scenario
(i) comprises three domains 1 , 2 , and 3 based on whether mden,ser is lower or higher than mcritden,ser (the
transition between the domains is indicated by the white-faced circle-shaped marker, representing t critini,& and
black-faced circle-shaped marker, representing t critend,& ), following Equations (A.5)–(A.7), whereas scenario
(ii) follows Equation (A.8).
For this purpose, administration intervals and doses are assumed to be constant, and the corre-
sponding initial conditions are periodic.6 Because of this regularity, only two different scenarios
have to be considered: at the end of the previous administration interval the denosumab serum con-
centration mden,ser is (i) lower than the critical concentration mcritden,ser, mden,ser < mcritden,ser, and (ii) it is
higher (or equal) mden,ser > mcritden,ser, see Figure A.1.
First, we investigate scenario (i). Denosumab is administered at the beginning of each adminis-
tration interval & , at t D tad,& , with tad,1 D 0. The administered dose and thus mden,sub are constant,
and at the end of each interval the denosumab serum concentration has dropped to a level below
the critical concentration, mden,ser < mcritden,ser. Consequently, each administration interval is char-
acterized by domains of different enzyme kinetics, analogous to the single-administration regime
elaborated in Sections 2.2 and A, which are delimited by the time instants at which the critical
concentration is reached, t critini,& and t critend,& , see also Figure A.1. The following notation is chosen for
the different enzyme degradation regimes: denotes the denosumab serum concentration if
tad,& 6 t 6 t critini,& , denotes the denosumab serum concentration if t critini,& 6 t 6 t critend,& , and
denotes the denosumab serum concentration if t critend,& 6 t 6 tad,&C1. While , ,
and are defined by Eqs. (A.2)–(A.4), , , and follow as
(A.5)
6For administration intervals and/or doses varying over time, the governing differential equations have to be solved in
piecewise fashion (administration interval after administration interval). In such case aid of numerical solution methods
is advisable. In clinical practice, such approach is, however, not standard, due to limited patient-friendliness.
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(A.6)
and
(A.7)
In scenario (ii) the denosumab serum concentration remains, after exceeding mcritden,ser at t critini in the
first administration interval, above mcritden,ser at all times. Thus, distinction between different domains
is, unlike scenario (i), not necessary, and only one analytic expression has to be derived. If & > 2,
m
&
den,ser reads as
m
&
den,ser D
mcritden,ser
korg
h
korge
korg.tCtcritini / C kenz.ekorg.tCtad,2/  1/
i
C
C mden,subkabs
korg.korg  kabs/.korg C kenz  kabs/

n
.kabs  korg/kenzekorgt
h
kenzt critini C ekabst
crit
ini Ckorgtad,2  e.korgCkenz/tcritini Ckorgtad,2
i
C
C korg.korg C kenz  kabs/
h
ekabst  ekorg.tCtad,2/ C ekabs.tCtad,2/
i

.k2org  korgkabs C kenzkabs/ekorg.tt
crit
ini /kabstcritini
o
C
CF.&/mden,subkabs
korg  kabs
&X
iD3
h
ekabs.tCtad,i /  ekorg.tCtad,i /
i
,
(A.8)
where function F.&/ is defined as F.&/ D 1 if & > 3 and F.&/ D 0 otherwise.
APPENDIX B: MODEL PARAMETERS
In Table B.1, the model parameters of the integrated systems biology/micromechanical model,
introduced in Section 3, that are explicitly mentioned in this paper, are summarized.
The bone formation rate kform is calibrated such that for the bone resorption rate, kres, defined
in Table B.1, steady-state cell concentrations, dCOBp=dt D dCOBa=dt D dCOCa=dt D 0, imply a
balanced bone turnover; that is, fvas D const. and fbm D const.: kform D kresCOCa=COBa . Calibration
of the proliferation rate POBp is described in detail in [24].
Furthermore, the stiffness tensor of the extravascular bone matrix, cbm, is defined in the line of
Fritsch and Hellmich [79]; based on the ultrasonics tests by Ashman et al. [89], conducted on human
femurs, cbm reads in compressed notation [90]
cbm D
0
BBBBB@
18.5 10.3 10.4 0 0 0
10.3 20.8 11.0 0 0 0
10.4 11.0 28.4 0 0 0
0 0 0 12.9 0 0
0 0 0 0 11.5 0
0 0 0 0 0 9.3
1
CCCCCA GPa . (A.9)
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Table B.1. Parameters of the integrated systems biology-micromechanical
model, see also [21, 32].
parameter numerical value unit
kres 2 (pM day)1
DOBu 7  102 d1
DOBp 1.6570  101 d1
DOCp 2.1  100 d1
AOBa 2.1107  101 d1
AOCa 5.6487  104 d1
Kd,[RANKL-d] 5.6797  100 pM
ˇRANKL 1.6842  102 pM d1QDRANKL 1.0132  101 d1
Ka,[RANKL-RANK] 3.4118  102 pM1
Ka,[RANKL-OPG] 1  103 pM1
M…mechact,OBp 0.5 –
 1.25 –
 105 pM/day
APPENDIX C: NOMENCLATURE
Abbreviations:
BALP bone-specific alkaline phosphatase
BCPM bone cell population model
BMD bone mineral density
CTx collagen type I cross-linked C-telopeptide
DXA dual-energy X-ray absorptiometry
NTx collagen type I cross-linked N-telopeptide
OBa active osteoblasts
OBp osteoblast precursor cells
OBu uncommitted osteoblast progenitor cells
OC osteocalcin
OCa active osteoclasts
OCp osteoclast precursor cells
OPG osteoprotegerin
PD pharmacodynamics
PINP procollagen type I N-terminal propeptide
PK pharmacokinetics
PMO postmenopausal osteoporosis
PTH parathyroid hormone
RANK receptor of nuclear factor kappa-B
RANKL ligand of RANK
RVE representative volume element
SED strain energy density
TGF-ˇ transforming growth factor beta
Latin symbols:
AOBa constant apoptosis rate of active osteoblasts
AOCa maximum apoptosis rate of active osteoclasts
cbm stiffness tensor of the extravascular bone matrix
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Cden molar concentration of denosumab
COBa molar concentration of active osteoblasts
COCa molar concentration of active osteoclasts
COPG molar concentration of OPG
CRANK molar concentration of RANK
CRANKL molar concentration of RANKL
C maxRANKL maximum molar concentration of RANKL
Dden dose of denosumab administrationQDRANKL constant RANKL degradation rate
DOBp maximum differentiation rate of osteoblast precursor cells
DOBu maximum differentiation rate of uncommitted osteoblast progenitor cells
DOCp maximum differentiation rate of osteoclast precursor cells
Ei Young’s moduli of bone on the macroscopic observation scale, i D 1, 2, 3
fbm volume fraction of extravascular bone matrix
Gij shear moduli of bone on the macroscopic observation scale, ij D 12, 23, 13
kabs absorption rate
kenz degradation rate related to enzymes
kform bone formation rate
korg degradation rate related to organs
kres bone resorption rate
Ka,ŒRANKL-i equilibrium association binding constant for the binding of RANKL to substance
i , i D denosumab, OPG, RANK
Kd,[RANKL-i equilibrium dissociation binding constant for the dissociation of substance i from
RANKL, i D denosumab, RANK
mden,ser denosumab mass concentration in the blood serum
mcritden,ser limit denosumab mass concentration in the blood serum
Mden molecular weight of denosumab
mden,sub increase of denosumab mass concentration in the blood serum due to administra-
tion
mden,sub denosumab mass concentration in the subcutaneous tissue
PRANKL production rate of RANKL
P PMORANKL PMO-related production rate of RANKL
P
PMO,ini
RANKL PMO-related production rate of RANKL directly after disease initiation
P mechRANKL mechanical disuse-related production rate of RANKL
POBp maximum proliferation rate of osteoblast precursor cells
t time variable
tPMO,ini point in time when PMO is initiated
Vbm volume of the extravascular bone matrix within a representative volume element
VRVE volume of the representative volume element
Vvas volume of the vascular pore space within a representative volume element
Greek symbols:
ˇRANKL intrinsic RANKL production rate
"bm microscopic strain tensor experienced by the extravascular bone matrix
 denosumab accessibility factor
 RANKL production inhibition parameter
 anabolic strength parameter

ij Poisson’s ratios of bone on the macroscopic observation scale, ij D 12, 13, 23
 parameter introduced for definition of 'RANKLPMO

TGF-ˇ
act,OBu activator function for the differentiation of uncommitted osteoblast progenitor
cells due to the action of TGF-ˇ
Copyright © 2013 John Wiley & Sons, Ltd. Int. J. Numer. Meth. Biomed. Engng. 2014; 30:1–27
DOI: 10.1002/cnm
24 S. SCHEINER ET AL.

TGF-ˇ
rep,OBp activator function for the differentiation of osteoblast precursor cells due to the
action of TGF-ˇ
RANKLact,OCp activator function for the differentiation of osteoclast precursor cells due to the
action of RANKL
…mechact,OBp activator function for the proliferation of osteoblast precursor cells due to mechan-
ical loading
M…mechact,OBp activator function for the proliferation of osteoblast precursor cells due to normal
mechanical loading
 bm microscopic stress tensor experienced by the extravascular bone matrix
& administration interval index in a multidose administration regime
† macroscopic stress tensor
RANKLPMO characteristic time of the RANKL production decrease
'mechPMO mechanoresponsiveness reduction factor
'RANKLPMO reduction factor P PMORANKL
‰bm strain energy density experienced on the observation scale of extravascular bone
matrix
M‰bm strain energy density experienced on the observation scale of extravascular bone
matrix related to normal mechanical loading
ACKNOWLEDGEMENTS
Financial support by the Australian Research Council, in the framework of the project Multi-scale mod-
eling of transport through deformable porous materials (project number DP-0988427), by the Australian
Academy of Science, in the framework of Scientific Visits to Europe with the COST Action program and by
the European Research Council, in the framework of the project Multiscale poro-micromechanics of bone
materials, with links to biology and medicine (project number FP7-257023), is gratefully acknowledged.
REFERENCES
1. Gerend M, Erchull M, Aiken L, Maner J. Reasons and risk: factors underlying women’s perceptions of susceptibility
to osteoporosis. Maturitas 2006; 55(3):227–237.
2. Delmas P. Treatment of postmenopausal osteoporosis. Lancet 2002; 359(9322):2018–2026.
3. Rubin M, Bilezikian J. New anabolic therapies in osteoporosis. Current Opinion in Rheumatology 2002;
14(4):433–440.
4. Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T, Garnero P, Bouxsein M, Bilezikian J, Rosen
C. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
New England Journal of Medicine 2003; 349(13):1207–1215.
5. Amgen Inc., 2011. Available from: www.amgen.com [Accessed 29 July 2013].
6. Boyce B, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Archives of Biochemistry
and Biophysics 2008; 473(2):139–146.
7. Martin R, Burr D, Sharkey N. Skeletal Tissue Mechanics. Springer Verlag: New York, USA, 1998.
8. Bekker P, Holloway D, Rasmussen A, Murphy R, Martin S, Leese P, Holmes G, Dunstan C, DePaoli A. A single-dose
placebo-controlled study of AMG 162, a fully human monclonal antibody to RANKL, in postmenopausal women.
Journal of Bone and Mineral Research 2004; 19(7):1059–1066.
9. McClung M, Lewiecki E, Cohen S, Bolognese M, Woodson G, Moffett A, Peacock M, Miller P, Lederman S,
Chesnut C, et al. Denosumab in postmenopausal women with low bone mineral density. New England Journal of
Medicine 2006; 354(8):821–831.
10. Body JJ, Facon T, Coleman R, Lipton A, Geurs F, Fan M, Holloway D, Peterson M, Bekker P. A study of the biolog-
ical receptor activator of nuclear factor-B ligand inhibitor, denosumab, in patients with multiple myeloma or bone
metastases from breast cancer. Clinical Cancer Research 2006; 12(4):1221–1228.
11. Lewiecki E, Miller P, McClung M, Cohen S, Bolognese M, Liu Y, Wang A, Siddhanti S, Fitzpatrick L. Two-year
treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Journal of Bone and Mineral Research 2007; 22(12):1832–1841.
12. Ellis G, Bone H, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S. Randomized trial of denosumab in
patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. Journal of Clinical Oncology 2008;
26(30):4875–4882.
13. U.S. Food and Drug Administration, 2011. Available from: www.fda.gov [Accessed 29 July 2013].
14. Holford N, Kimko H, Monteleone J, Peck C. Simulation of clinical trials. Annual Review of Pharmacology and
Toxicology 2000; 40:209–234.
Copyright © 2013 John Wiley & Sons, Ltd. Int. J. Numer. Meth. Biomed. Engng. 2014; 30:1–27
DOI: 10.1002/cnm
MATHEMATICAL MODELING OF OSTEOPOROSIS TREATMENT BY DENOSUMAB 25
15. Mould D, Sweeney K. The pharmacokinetics and pharmacodynamics of monoclonal antibodies – mechanistic
modeling applied to drug development. Current Opinion in Drug Discovery and Development 2007; 10(1):84–96.
16. Post T, Cremers S, Kerbusch T, Danhof M. Bone physiology, disease and treatment – towards disease system analysis
in osteoporosis. Clinical Pharmacokinetics 2010; 49(2):89–118.
17. Sheiner L. Learning versus confirming in clinical drug development. Clinical Pharmacology and Therapeutics 1997;
61(3):275–291.
18. Sharma A, Jusko W. Characterization of four basic models of indirect pharmacodynamic responses. Journal of
Pharmacokinetics and Biopharmaceutics 1996; 24(6):611–635.
19. Post T, Freijer J, DeJongh J, Danhof M. Disease system analysis: basic disease progression models in degenerative
disease. Pharmaceutical Research 2005; 22(7):1038–1049.
20. Marathe A, Peterson M, Mager D. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in
multiple myeloma patients. Journal of Pharmacology and Experimental Therapeutics 2008; 326(2):555–562.
21. Pivonka P, Zimak J, Smith D, Gardiner B, Dunstan C, Sims N, Martin T, Mundy G. Theoretical investigation of the
role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology 2010; 262(2):306–316.
22. Peterson M, Riggs M. Predicting nonlinear changes in bone mineral density over time using a multscale systems
pharmacology model. Pharmacometrics & Systems Pharmacology 2012; 1:1–8.
23. Robling A, Castillo A, Turner C. Biomechanical and molecular regulation of bone remodeling. Annual Review of
Biomedical Engineering 2006; 8:455–498.
24. Scheiner S, Pivonka P, Hellmich C. Coupling systems biology with multiscale mechanics, for computer simulations
of bone remodeling. Computer Methods in Applied Mechanics and Engineering 2013; 254:181–196.
25. Shargel L, Wu-Pong S, Yu A. Applied Biopharmaceutics & Pharmacokinetics, 5th ed. McGraw-Hill: New York,
USA, 2005.
26. Lewiecki E. Treatment of osteoporosis with denosumab. Maturitas 2010; 66(2):182–186.
27. Murray J. Mathematical Biology – I: An Introduction, 3rd ed. Springer Science and Business Media, Inc.:
Berlin, Germany, 2002.
28. Schwefel HP. Numerische Optimierung von Computer-Modellen mittels der Evolutionsstrategie [Numerical Opti-
mization of Computer Models by means of the Evolution Strategy]. Birkhäuser Verlag: Basel, Switzerland and
Stuttgart, Germany, 1977. In German.
29. McDowell M, Fryar C, Ogden C, Flegal K. Anthropometric reference data for children and adults: United states,
2003–2006, National Health Statistics Reports, No. 10, Centers for Disease Control and Prevention, 2008.
30. Cirillo M, Laurenzi M, Tervisan M, Stamler J. Hematocrit, blood pressure, and hypertension: the Gubbio population
study. Hypertension 1992; 20(3):319–326.
31. Lemaire V, Tobin F, Greller L, Cho C, Suva L. Modeling of the interactions between osteoblast and osteoclast
activities in bone remodeling. Journal of Theoretical Biology 2004; 229(3):293–309.
32. Pivonka P, Zimak J, Smith D, Gardiner B, Dunstan C, Sims N, Martin T, Mundy G. Model structure and control of
bone remodeling: a theoretical study. Bone 2008; 43(2):249–263.
33. Pivonka P, Buenzli P, Scheiner S, Hellmich C, Dunstan C. The influence of bone surface availability in bone
remodelling – a mathematical model including coupled geometrical and biomechanical regulations of bone cells.
Engineering Structures 2013; 47:134–147.
34. Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-ˇ1 to the bone. Endocrine Reviews
2005; 26(6):743–774.
35. Erlebacher A, Filvaroff E, Ye JQ, Derynck R. Osteoblastic responses to TGF-ˇ during bone remodeling. Molecular
Biology of the Cell 1998; 9(7):1903–1918.
36. Jones D, Nolte H, Scholübbers JG, Turner E, Veltel D. Biochemical signal transduction of mechanical strain in
osteoblast-like cells. Biomaterials 1991; 12(2):101–110.
37. Owan I, Burr D, Turner C, Qiu J, Tu Y, Onyia J, Duncan R. Mechanotransduction in bone: osteoblasts are
more responsive to fluid forces than mechanical strain. American Journal of Physiology - Cell Physiology 1997;
273(3):C810–C815.
38. Kaspar D, Seidl W, Neidlinger-Wilke C, Beck A, Claes L, Ignatius A. Proliferation of human-derived osteoblast-like
cells depends on the cycle number and frequency of uniaxial strain. Journal of Biomechanics 2002; 35(7):873–880.
39. Weyts F, Bosmans B, Niesing R, Van JL, Weinans H. Mechanical control of human osteoblast apoptosis and
proliferation in relation to differentiation. Calcified Tissue International 2003; 72(4):505–512.
40. Fuller K, Lean J, Bayley K, Wani M, Chambers T. A role for TGF-ˇ1 in osteoclast differentiation and survival.
Journal of Cell Science 2000; 113(13):2445–2453.
41. Pitsillides A, Rawlinson S, Suswillo R, Bourrin S, Zaman G, Lanyon L. Mechanical strain-induced NO production
by bone cells: a possible role in adaptive bone (re)modeling? FASEB Journal 1995; 9(15):1614–1622.
42. Mullender M, El Haj A, Yang Y, van Duin M, Burger E, Klein-Nulend J. Mechanotransduction of bone cells in vitro:
mechanobiology of bone tissue. Medical and Biological Engineering and Computing 2004; 42(1):14–21.
43. Fan X, Roy E, Zhu L, Murphy T, Ackert-Bicknell C, Hart C, Rosen C, Nanes M, Rubin J. Nitric oxide regulates recep-
tor activator of nuclear factor-B ligand and osteoprotegerin expression in bone marrow stromal cells. Endocrinology
2004; 145(2):751–759.
44. Liu C, Zhao Y, Cheung WY, Gandhi R, Wang L, You L. Effects of cyclic hydraulic pressure on osteocytes. Bone
2010; 46(5):1449–1456.
Copyright © 2013 John Wiley & Sons, Ltd. Int. J. Numer. Meth. Biomed. Engng. 2014; 30:1–27
DOI: 10.1002/cnm
26 S. SCHEINER ET AL.
45. Alon U. An Introduction to Systems Biology: Design Principles of Biological Circuits. Chapman & Hall: London,
UK, 2007.
46. Wergedal J, Baylink D. Electron microprobe measurements of bone mineralization rate in vivo. American Journal of
Physiology 1974; 226(2):345–352.
47. Grynpas M. Age and disease-related changes in the mineral of bone. Calcified Tissue International 1993;
53(S1):57–64.
48. Busa B, Miller L, Rubin C, Qin YX, Judex S. Rapid establishment of chemical and mechanical properties during
lamellar bone formation. Calcified Tissue International 2005; 77(6):386–394.
49. Hellmich C, Kober C, Erdmann B. Micromechanics-based conversion of CT data into anisotropic elasticity tensors,
applied to FE simulations of a mandible. Annals of Biomedical Engineering 2008; 36(1):108–122.
50. Zaoui A. Continuum micromechanics: survey. Journal of Engineering Mechanics (ASCE) 2002; 128(8):808–816.
51. Riggs B, Khosla S, Melton III L. A unitary model for involutional osteoporosis: estrogen deficiency causes both type
I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. Journal of Bone and
Mineral Research 1998; 13(5):763–773.
52. Manolagas S. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and
treatment of osteoporosis. Endocrine Reviews 2000; 21(2):115–137.
53. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas P. Increased bone turnover in late postmenopausal women is a
major determinant of osteoporosis. Journal of Bone and Mineral Research 1996; 11(3):337–349.
54. Hofbauer L, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular
diseases. Journal of the American Medical Association 2004; 292(4):490–495.
55. Riggs B. The mechanisms of estrogen regulation of bone resorption. The Journal of Clinical Investigation 2000;
106(10):1203–1204.
56. Tomkinson A, Gevers E, Wit J, Reeve J, Noble B. The role of estrogen in the control of rat osteocyte apoptosis.
Journal of Bone and Mineral Research 1998; 13(8):1243–1250.
57. Kostenuik P, Nguyen H, McCabe J, Warmington K, Kurahara C, Sun N, Chen C, Li L, Cattley R, Van G,
et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in
knock-out mice that express chimeric (murine/human) RANKL. Journal of Bone and Mineral Research 2009; 24(2):
182–195.
58. Atkins P. Physical Chemistry, 6th ed. Oxford University Press: Oxford, UK, 1998.
59. Green W. Denosumab (Prolia) injection – a new approach to the treatment of women with postmenopausal
osteoporosis. Pharmacy and Therapeutics 2010; 35(10):553–559.
60. Bonnet N, Ferrari S. Exercise and the skeleton: how it works and what it really does. IBMS BoneKey 2010;
7(7):235–248.
61. Lekhnitskii S. Theory of Elasticity of an Anisotropic Elastic Body. Holden-Day, Inc.: San Francisco, USA, 1963.
62. Looker A, Bauer D, Chesnut III C, Gundberg C, Hochberg M, Klee G, Kleerekoper M, Watts N, Bell N. Clinical use
of biochemical markers of bone remodeling: current status and future directions. Osteoporosis International 2000;
11(6):467–480.
63. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung M, Reid I, Resch H, Siris E, Uebelhart D,
Wang A, Weryha G, Cummings S. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Journal of Bone and Mineral Research 2011; 26(3):530–537.
64. Lu Y, Genant HK, Sheperd J, Zhao S, Mathur A, Fuerst T, Cummings SR. Classification of osteoporosis based on
bone mineral densities. Journal of Bone and Mineral Research 2001; 16(5):901–910.
65. Bone H, Bolognese M, Yuen C, Kendler D, Wang H, Liu Y, Martin J. Effects of denosumab on bone mineral
density and bone turnover in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 2008;
93(6):2149–2157.
66. Kendler D, Roux C, Benhamou C, Brown J, Lillelstol M, Siddhanti S, Man HS, Martin J, Bone H. Effects of deno-
sumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.
Journal of Bone and Mineral Research 2010; 25(1):72–81.
67. Miller P. Denosumab: anti-RANKL antibody. Current Osteoporosis Reports 2009; 7(1):18–22.
68. Miller P, Wagman R, Peacock M, Lewiecki E, Bolognese M, Weinstein R, Ding B, Martin J, McClung M. Effect of
denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical
trial. Journal of Clinical Endocrinology and Metabolism 2011; 96(2):394–402.
69. Bala Y, Farlay D, Delmas P, Meunier P, Boivin G. Time sequence of secondary mineralization and microhardness
in cortical and cancellous bone from ewes. Bone 2010; 46(4):1204–1212.
70. Vuong J, Hellmich C. Bone fibrillogenesis and mineralization: quantitative analysis and implications for tissue
elasticity. Journal of Theoretical Biology 2011; 287:115 –130.
71. Chavassieux P, Arlot M, Reda C, Wei L, Yates A, Meunier P. Histomorphometric assessment of the long-term effects
of alendronate on bone quality and remodeling in patients with osteoporosis. The Journal of Clinical Investigation
1997; 100(6):1475–1480.
72. Stepan J, Alenfeld F, Boivin G, Feyen J, Lakatos P. Mechanisms of action of antiresorptive therapies of
postmenopausal osteoporosis. Endocrine Regulations 2003; 37(4):225–238.
73. Seeman E. Reduced bone formation and increased bone resorption: rational targets for the treatment of osteoporosis.
Osteoporosis International 2003; 14(S2-S8).
Copyright © 2013 John Wiley & Sons, Ltd. Int. J. Numer. Meth. Biomed. Engng. 2014; 30:1–27
DOI: 10.1002/cnm
MATHEMATICAL MODELING OF OSTEOPOROSIS TREATMENT BY DENOSUMAB 27
74. Boivin G, Meunier P. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporosis
International 2003; 14:S19–S24.
75. Bone H, Hosking D, Devogelaer JP, Tucci J, Emkey R, Tonino R, Rodriguez-Portales J, Downs R, Gupta J,
Santora A, Liberman U. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. The
New England Journal of Medicine 2004; 350(12):1189–1199.
76. Lewiecki E, Silverman S. Redefining osteoporosis treatment: who to treat and how long to treat. Arquivos Brasileiros
de Endocrinologia & Metabologia 2006; 50(4):694–704.
77. Fuchs R, Faillace M, Allen M, Phipps R, Miller L, Burr D. Biphosphonates do not alter the rate of secondary
mineralization. Bone 2011; 49(4):701–705.
78. Muschitz C, Kocijan R, Fahrleitner-Pammer A, Lung S, Resch H. Antiresorptives overlapping ongoing teriparatide
treatment result in additional increases in bone mineral density. Journal of Bone and Mineral Research 2013;
28(1):196–205.
79. Fritsch A, Hellmich C. ‘Universal’ microstructural patterns in cortical and trabecular, extracellular and extravascu-
lar bone materials: micromechanics-based prediction of anisotropic elasticity. Journal of Theoretical Biology 2007;
244(4):597–620.
80. Bonewald L, Johnson M. Osteocytes, mechanosensing and Wnt signaling. Bone 2008; 42(4):606–615.
81. Bonewald L. The amazing osteocyte. Journal of Bone and Mineral Research 2011; 26(2):229–238.
82. Jacobs C, Temiyasathit S, Castillo A. Osteocyte mechanobiology and pericellular mechanics. Annual Review of
Biomedical Engineering 2010; 12:369–400.
83. Moroz A, Crane M, Smith G, Wimpenny D. Phenomenological model of bone remodeling cycle containing osteocyte
regulation loop. Biosystems 2006; 84(3):183–190.
84. Rieger R, Hambli R, Jennane R. Modeling of biological doses and mechanical effects on bone transduction. Journal
of Theoretical Biology 2011; 274(1):36–42.
85. Hambli R, Rieger R. Physiologically based mathematical model of transduction of mechanobiological signals by
osteocytes. Biomechanics and Modeling in Mechanobiology 2012; 11(1-2):83–93.
86. Graham J, Ayati B, Holstein S, Martin J. The role of osteocytes in targeted bone remodeling: a mathematical model.
PLoS ONE 2013; 8(5):e63884, 1–10.
87. Klein-Nulend J, Van der Plas A, Semeins C, Ajubi N, Frangos J, Nijweide P, Burger E. Sensitivity of osteocytes to
biomechanical stress in vitro. FASEB Journal 1995; 9(5):441–445.
88. Klein-Nulend J, Bacabac R, Bakker A. Mechanical loading and how it affects bone cells: the role of the osteocyte
cytoskeleton in maintaining our skeleton. European Cells and Materials 2012; 24:278–291.
89. Ashman R, Cowin S, Van Buskirk W, Rice J. A continuous wave technique for the measurement of the elastic
properties of cortical bone. Journal of Biomechanics 1984; 17(5):349–361.
90. Cowin S, Mehrabadi M. The structure of the linear anisotropic elastic symmetries. Journal of the Mechanics and
Physics of Solids 1992; 40(7):1459–1471.
Copyright © 2013 John Wiley & Sons, Ltd. Int. J. Numer. Meth. Biomed. Engng. 2014; 30:1–27
DOI: 10.1002/cnm
